Pharmather Archives | the deep dive

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th. Maxim Group initiated coverage on

PharmaTher Holdings (CSE: PHRM) this morning announced that it continues to push forward with the development of Ketabet. The company

PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The arrangement will see the two

PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA for orphan drug designation as

PharmaTher Holdings (CSE: PHRM) has seen the US FDA approve the firms application for an investigational new drug. The approval

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the filing of a provisional patent

PharmaTher Holdings (CSE: PHRM) is looked to complete a phase two clinical trial. The company this morning announced the submittal

PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into a sponsored research agreement. The agreement, which was

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related to psychedelics. The company this

PharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to that of Revive Therapeutics (CSE: